These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 7679778)

  • 1. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
    Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA; Kellam P; Kemp SD
    Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.
    Hanna GJ; Johnson VA; Kuritzkes DR; Richman DD; Brown AJ; Savara AV; Hazelwood JD; D'Aquila RT
    J Infect Dis; 2000 Mar; 181(3):904-11. PubMed ID: 10720511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations.
    Tamalet C; Yahi N; Tourrès C; Colson P; Quinson AM; Poizot-Martin I; Dhiver C; Fantini J
    Virology; 2000 May; 270(2):310-6. PubMed ID: 10792990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple whammy. Will an AIDS therapy live up to its advance billing?
    Rennie J
    Sci Am; 1993 May; 268(5):18, 22. PubMed ID: 7683141
    [No Abstract]   [Full Text] [Related]  

  • 7. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
    Masquelier B; Pellegrin I; Ruffault A; Ragnaud JM; Morlat P; Michelet C; Doignon F; Biteau N; Fleury HJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):330-4. PubMed ID: 7533640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
    Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates.
    Rezende LF; Prasad VR
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1716-34. PubMed ID: 15183340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.
    Eron JJ; Chow YK; Caliendo AM; Videler J; Devore KM; Cooley TP; Liebman HA; Kaplan JC; Hirsch MS; D'Aquila RT
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1480-7. PubMed ID: 7689822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
    Dis Markers; 1990; 8(3):163-4. PubMed ID: 1703061
    [No Abstract]   [Full Text] [Related]  

  • 13. Viral resistance and the selection of antiretroviral combinations.
    Larder BA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S28-33. PubMed ID: 8595505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular basis and clinical significance of HIV-1 resistance to nucleoside compounds].
    Wainberg MA; Gu Z; Salomon H; Arts EJ; Kleiman L; Parniak MA; Morin N
    C R Acad Sci III; 1995 Mar; 318(3):315-28. PubMed ID: 7540494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
    Gu Z; Gao Q; Li X; Parniak MA; Wainberg MA
    J Virol; 1992 Dec; 66(12):7128-35. PubMed ID: 1279198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single- and multidrug resistance mutations to reverse transcriptase and protease inhibitors: human immunodeficiency virus type 1-infected patients from two geographical areas in Spain. Spanish Groups for Antiretroviral Resistance Studies.
    Pérez-Alvarez L; Villahermosa ML; Cuevas MT; Delgado E; Manjón N; Vázquez de Parga E; Medrano L; Contreras G; Thomson MM; Colomo C; Taboada JA; Nájera R
    J Hum Virol; 2000; 3(3):150-6. PubMed ID: 10881995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 drug resistance. Molecular pathogenesis and laboratory monitoring.
    D'Aquila RT
    Clin Lab Med; 1994 Jun; 14(2):393-422. PubMed ID: 7523021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.